西普金奖荣耀加冕，麝香保心丸的传承与创新之路

Group 1: Conference Overview - The 18th Health Industry (International) Ecological Conference, known as the 2025 Xipu Conference, was held in Boao, Hainan, from August 16 to 21, focusing on the theme "Rapid Transformation, Crossing New Cycles - Reconstruction of Growth Drivers and Evolution of Industrial Ecology" [1] - The conference aims to explore how the health industry can achieve a leap from "single-point innovation" to "comprehensive transformation" amid pressures on traditional growth models and the reshaping of industry patterns by emerging technologies [1] Group 2: Product Recognition - The "2025 Health China Brand List" was announced during the conference, with Shanghai Huan Pharmaceutical's flagship product, "Shangyao Brand" Musk Heart Pill, receiving the highest honor, the "Xipu Gold Award" [1][10] Group 3: Product Development and Research - The Musk Heart Pill is derived from the Song Dynasty's "Suhexiang Pill" and has been modernized through continuous optimization by a team from Fudan University [3] - The formulation includes artificial musk, ginseng extract, artificial beef bile, cinnamon, suhexiang, toad venom, and borneol, demonstrating clear pharmacological effects and mechanisms [3] - The product has established a modern research system based on evidence-based medicine, accumulating substantial scientific evidence over the years [3][10] Group 4: Clinical Research Findings - The MUST study, a large-scale evidence-based research project, involved 2,673 stable coronary artery disease (CAD) patients across 97 hospitals, showing that the Musk Heart Pill significantly improves clinical outcomes when combined with conventional Western medicine [4] - The MUST-D subgroup analysis focused on CAD patients with diabetes, revealing a 45.8% reduction in major adverse cardiovascular events (MACE) compared to the placebo group [5] - The MUST-E study highlighted the economic advantages of the Musk Heart Pill, indicating lower long-term costs and higher health outcomes compared to placebo [6] Group 5: Gender and Weight-Specific Analyses - The MUST-F subgroup analysis indicated that the Musk Heart Pill significantly reduces MACE rates in female CAD patients, with a 0.5% occurrence compared to 2.6% in the placebo group [7] - The MUST-W subgroup analysis found a 75.4% reduction in MACE rates for CAD patients weighing less than 65 kg, suggesting the need for personalized treatment for those weighing 65 kg or more [8] Group 6: Broader Impact and Future Research - The LESS study evaluated the Musk Heart Pill's efficacy in patients with angina and non-obstructive coronary artery disease (ANOCA), showing significant improvements in angina symptoms and quality of life [9] - The ongoing research and recognition of the Musk Heart Pill contribute to its growing global influence, setting a precedent for the modernization and internationalization of traditional Chinese medicine [9][10]